Compare MobilEye Global Inc (MBLY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $6.00B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MBLY | XBI | |
|---|---|---|
Market Cap | $6.00B | $10.11B |
Volume | 7,007,849 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $15.42 | $169.55 |
52-Week Low | $6.56 | $104.99 |
Typical Hold Time | 15 Days | 38 Days |
Enterprise Value | $4.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.06, down 1.26% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $1.9B in 2025 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus leans bullish with a $10.83 price target, while institutional activity shows mixed positioning amid autonomous driving sector volatility.
MBLY presents a high-risk opportunity with substantial upside potential if profitability improves, but current negative margins and bearish technicals suggest caution. The autonomous driving market position remains strong, though execution risks and competitive pressures could limit near-term gains despite Wall Street's optimistic price targets.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
